|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009247,
umls-concept:C0010592,
umls-concept:C0022341,
umls-concept:C0030705,
umls-concept:C0034902,
umls-concept:C0205225,
umls-concept:C0332240,
umls-concept:C0439661,
umls-concept:C0443252,
umls-concept:C0681804,
umls-concept:C1257890,
umls-concept:C1274040
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2007-7-25
|
|
pubmed:abstractText |
Cyclosporine A (CsA) has become one of the leading agents for the treatment of pure red cell aplasia (PRCA). However, further studies are necessary to determine the relapse-free survival (RFS) and overall survival (OS) of patients treated with this drug, the minimum duration of therapy for induction of remission, and whether or not there is need for maintenance treatment.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:BesshoMasamiM,
pubmed-author:DanKazuoK,
pubmed-author:FujishimaNaohitoN,
pubmed-author:HirokawaMakotoM,
pubmed-author:NakaoShinjiS,
pubmed-author:OmineMitsuhiroM,
pubmed-author:OzawaKeiyaK,
pubmed-author:PRCA Collaborative Study Group,
pubmed-author:SawadaKen-ichiK,
pubmed-author:TeramuraMasanaoM,
pubmed-author:TsurumiHisashiH,
pubmed-author:UrabeAkioA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
92
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1021-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17640861-Adolescent,
pubmed-meshheading:17640861-Adrenal Cortex Hormones,
pubmed-meshheading:17640861-Adult,
pubmed-meshheading:17640861-Aged,
pubmed-meshheading:17640861-Aged, 80 and over,
pubmed-meshheading:17640861-Autoimmune Diseases,
pubmed-meshheading:17640861-Cohort Studies,
pubmed-meshheading:17640861-Cyclophosphamide,
pubmed-meshheading:17640861-Cyclosporine,
pubmed-meshheading:17640861-Disease-Free Survival,
pubmed-meshheading:17640861-Drug Evaluation,
pubmed-meshheading:17640861-Female,
pubmed-meshheading:17640861-Follow-Up Studies,
pubmed-meshheading:17640861-Health Surveys,
pubmed-meshheading:17640861-Hematologic Neoplasms,
pubmed-meshheading:17640861-Humans,
pubmed-meshheading:17640861-Immunosuppressive Agents,
pubmed-meshheading:17640861-Japan,
pubmed-meshheading:17640861-Male,
pubmed-meshheading:17640861-Middle Aged,
pubmed-meshheading:17640861-Myelodysplastic Syndromes,
pubmed-meshheading:17640861-Preleukemia,
pubmed-meshheading:17640861-Recurrence,
pubmed-meshheading:17640861-Red-Cell Aplasia, Pure,
pubmed-meshheading:17640861-Remission Induction,
pubmed-meshheading:17640861-Salvage Therapy,
pubmed-meshheading:17640861-Survival Analysis,
pubmed-meshheading:17640861-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group.
|
|
pubmed:affiliation |
Division of Haematologyand Oncology, Department of Medicine,Akita University School of Medicine,1-1-1 Hondo, Akita, Japan. ksawada@doc.med.akita- u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
